Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 20 (1), 295

Usefulness of Mid-Week Hemoglobin Measurement for Anemia Management in Patients Undergoing Hemodialysis: A Retrospective Cohort Study

Affiliations

Usefulness of Mid-Week Hemoglobin Measurement for Anemia Management in Patients Undergoing Hemodialysis: A Retrospective Cohort Study

Soo Ya Bae et al. BMC Nephrol.

Abstract

Background: Short-term hemoglobin (Hb) variability related to volume status is observed in chronic kidney disease (CKD) patients receiving hemodialysis (HD). Given the lack of studies regarding outcomes according to the day of Hb sampling, the existing guidelines do not strongly recommend regarding measurement timing. Pre-dialysis mid-week sampling (Wednesday and Thursday) is preferable to minimize short-term Hb variability, although numerous HD centers perform early-week sampling (Monday and Tuesday). The different measurement days may influence the prescribed dose of erythropoiesis-stimulating agent (ESA) and related patient outcomes. We investigated changes in Hb levels and ESA doses according to the Hb measurement day among HD patients.

Methods: Starting September 2013, the day for pre-dialysis Hb measurement at the Asan Medical Center was changed from early-week days to mid-week days. This single-center retrospective study evaluated medical records of 92 patients who received maintenance HD between September 2012 and August 2014.

Results: There was no significant difference in the mean Hb levels between early-week days and mid-week days (10.71 ± 0.06 g/dL vs. 10.78 ± 0.47 g/dL, p = 0.105). However, the mean doses of darbepoetin-α on early-week days were higher than those on mid-week days (175.4 ± 72.5 μg/month vs. 163.7 ± 83.6 μg/month, p = 0.022). The mean doses of intravenous iron hydroxide sucrose for early-week measurements were also higher than those for mid-week measurements (623.0 ± 489.0 mg/year vs. 447.0 ± 505.2 mg/year, p = 0.001). The mean interdialytic weight gains were 2.81 ± 0.82 kg on early-week days and 1.99 ± 0.61 kg on mid-week days (p < 0.001).

Conclusions: Compared with early-week measurements, mid-week pre-dialysis Hb measurements were significantly associated with lower ESA doses without a change in Hb levels.

Keywords: Anemia; Chronic kidney disease; Erythropoiesis-stimulating agent; Hemodialysis; Hemoglobin.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Hemoglobin levels according to hemoglobin measurement day. There was no significant difference in the mean hemoglobin levels between the early-week and mid-week measurements
Fig. 2
Fig. 2
Mean doses of erythropoiesis-stimulating agents before and after changing the hemoglobin measurement day. The mean dose of darbepoetin-α alfa was significantly higher for early-week days than for mid-week days. ESA, erythropoiesis-stimulating agent
Fig. 3
Fig. 3
Interdialytic body weight gains according to hemoglobin measurement day. There was a significant difference in the mean interdialytic weight gains between the early-week and mid-week measurements. ΔBwt, interdialytic body weight gain

Similar articles

See all similar articles

References

    1. KDOQI; National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11. doi: 10.1053/j.ajkd.2006.03.010. - DOI - PubMed
    1. Babitt JL, Lin HY. Mechanisms of anemia in chronic kidney disease. J Am Soc Nephrol. 2012;23:1631–1634. doi: 10.1681/ASN.2011111078. - DOI - PMC - PubMed
    1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175–1178. doi: 10.1016/S0140-6736(86)92192-6. - DOI - PubMed
    1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78. doi: 10.1056/NEJM198701083160203. - DOI - PubMed
    1. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. doi: 10.1056/NEJMoa062276. - DOI - PubMed

LinkOut - more resources

Feedback